Palisade Bio Presents Development Overview Of PALI-2108 At The IBD Innovate: Product Development For Crohn's & Colitis April 9-10, 2024 In Cambridge, MA
Portfolio Pulse from Benzinga Newsdesk
Palisade Bio, Inc. (NASDAQ:PALI) presented an overview of PALI-2108, a treatment for moderate-to-severe ulcerative colitis, at the IBD Innovate conference in Cambridge, MA. The presentation, given by the company's CEO and Chief Medical Officer, highlighted the drug's development, its unique positioning, and the pathway towards late-stage development. PALI-2108, a colon-specific PDE4 inhibitor prodrug, is advancing towards a Phase 1 clinical study by the end of the year, supported by a $500,000 funding agreement with Giiant from the US Crohn's and Colitis Foundation.
April 10, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Palisade Bio, Inc. (NASDAQ:PALI) discussed the development of PALI-2108 for ulcerative colitis at the IBD Innovate conference, highlighting its progress towards Phase 1 clinical trials and funding support from the US Crohn's and Colitis Foundation.
The presentation of PALI-2108 at a premier conference and the advancement towards Phase 1 clinical trials are positive indicators of the drug's potential and Palisade Bio's progress in the biopharmaceutical field. The support from the US Crohn's and Colitis Foundation through a significant funding agreement further validates the potential of PALI-2108 and could positively influence investor sentiment towards PALI in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100